Oral antidiabetic agents. A guide to selection

Area of Science:

• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) arises from complex interactions affecting insulin secretion and action.
• Pharmacological agents offer diverse mechanisms to improve glucose homeostasis.

Purpose of the Study:

• To review pharmacological approaches for managing type 2 diabetes mellitus.
• To guide the selection and combination of oral antihyperglycemic agents based on patient profiles and drug properties.

Main Methods:

• Review of pharmacological agents including sulphonylureas, biguanides (metformin), alpha-glucosidase inhibitors (acarbose), and thiazolidinediones (troglitazone).
• Analysis of treatment strategies based on patient characteristics (e.g., glycemic severity, obesity, insulin resistance, renal impairment) and drug efficacy/safety profiles.
• Consideration of combination therapy with insulin for secondary treatment failure.

Main Results:

• Different drug classes target specific pathophysiological defects in T2DM.
• Treatment selection should be individualized: metformin, acarbose, or thiazolidinediones for mild hyperglycemia; sulphonylureas for severe hyperglycemia.
• Metformin and thiazolidinediones are prioritized for obese, insulin-resistant patients; sulphonylureas for non-obese patients.
• Acarbose is beneficial for post-prandial glucose control.
• Combination therapy with insulin may be necessary.
• Safety considerations are crucial for elderly patients and those with renal impairment, particularly regarding sulphonylureas and metformin.

Conclusions:

• Individualized selection and combination of oral antihyperglycemic agents are key to effective T2DM management.
• Tailoring therapy based on patient-specific factors and drug characteristics optimizes glycemic control and minimizes risks.
• Careful consideration of safety profiles is essential, especially in vulnerable patient populations.